CSPC Innovation Pharmaceutical Co., Ltd. (300765) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

CSPC Innovation Pharmaceutical Co., Ltd.

Why is CSPC Innovation Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 9.52% and Operating profit at -212.79% over the last 5 years

The company has declared negative results for the last 6 consecutive quarters

NET PROFIT(HY) At CNY 2.4 MM has Grown at -96.01%
OPERATING CASH FLOW(Y) Lowest at CNY -449.2 MM
ROCE(HY) Lowest at -2.92%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -24.32%, its profits have fallen by -235.6%
At the current price, the company has a high dividend yield of 0

Underperformed the market in the last 1 year

Even though the market (China Shanghai Composite) has generated returns of 13.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -24.32% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in FMCG)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is CSPC Innovation Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

CSPC Innovation Pharmaceutical Co., Ltd.

-20.0%

-0.12

63.47%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.52%

EBIT Growth (5y)

-212.79%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.33

Sales to Capital Employed (avg)

0.55

Tax Ratio

17.28%

Dividend Payout Ratio

51.81%

Pledged Shares

Institutional Holding

ROCE (avg)

21.16%

ROE (avg)

8.09%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

18.11

EV to EBIT

-116.46

EV to EBITDA

-191.65

EV to Capital Employed

29.98

EV to Sales

32.35

PEG Ratio

Dividend Yield

0.03%

ROCE (Latest)

-25.74%

ROE (Latest)

-14.00%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at CNY 2.4 MM

RAW MATERIAL COST(Y)

Fallen by -22.36% (YoY

-27What is not working for the Company

NET PROFIT(HY)

At CNY 2.4 MM has Grown at -96.01%

OPERATING CASH FLOW(Y)

Lowest at CNY -449.2 MM

ROCE(HY)

Lowest at -2.92%

INVENTORY TURNOVER RATIO(HY)

Lowest at 3.51 times

DEBT-EQUITY RATIO (HY)

Highest at -29.74 %

INTEREST(Q)

Highest at CNY 6.35 MM

Here's what is working for CSPC Innovation Pharmaceutical Co., Ltd.

Net Profit

Higher at CNY 2.4 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Raw Material Cost

Fallen by -22.36% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for CSPC Innovation Pharmaceutical Co., Ltd.

Net Profit

At CNY 2.4 MM has Grown at -96.01%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Operating Cash Flow

Lowest at CNY -449.2 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

At CNY 6.35 MM has Grown at 68.45%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Inventory Turnover Ratio

Lowest at 3.51 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Interest

Highest at CNY 6.35 MM

in the last five periods and Increased by 68.45% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at -29.74 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio